Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
-$0.01 today
- Market cap
- $116.77M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
Volume 11.56M
Average 2.73M
INO Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Inovio Pharmaceuticals, Inc.NASDAQ: INO
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit turns negative
Q1 FY2026 gross profit was -$745.46K, compared with $65.34K a year earlier. Trailing-twelve-month gross profit was -$2.24M. Over 3 fiscal years it compounded at -81.5% a year.
Context
- Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
- Gross profit increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near -$745.46K or moves back toward the trailing-twelve-month quarterly average of -$560.3K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 65.34K USD
- Year-over-year change
- -70.0%
- 4-year CAGR
- -56.2%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 65.34K | -70.0% |
| FY2024 | 2024-12-31 | 217.76K | -73.8% |
| FY2023 | 2023-12-31 | 832.01K | -91.9% |
| FY2022 | 2022-12-31 | 10.26M | +478.2% |
| FY2021 | 2021-12-31 | 1.77M | — |
Gross Profit vs competitors
How INO compares with its peers on the latest reported figures
- INO's LTM Mar 2026 gross profit of -$2.24M is the 8th highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of -69.6% is the 8th highest of 9, against a peer median of +62.4%.
- Over three fiscal years its annual growth of -81.5% compares with a peer median of -11.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $64.58M | +289.3% | — | 52.1% | |
| LTM Mar 2026 | $54.77M | +162.7% | +7.1% | 100.0% | |
| LTM Mar 2026 | $7.26M | +61.1% | +70.5% | 48.3% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $5.95M | +1.3% | -29.1% | 49.6% |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | -$46K | -4.5% | — | — | |
| LTM Mar 2026 | -$240K | +97.6% | — | 20.9% | |
| LTM Mar 2026 | -$2.24M | -69.6% | -81.5% | — | |
| LTM Mar 2026 | -$11.28M | -289.4% | -56.0% | 61.2% | |
| LTM Mar 2026 | -$26.26M | +63.7% | — | 415.8% | |
| Peer median (excluding INO) | $0 | +62.4% | -11.0% | 52.1% | |
Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.77M | 10.26M | 832.01K | 217.76K | 65.34K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.77M | 10.26M | 832.01K | 217.76K | 65.34K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 249.24M | 187.65M | 86.68M | 75.62M | 54.21M |
| Selling, General & Admin | 53.75M | 90.19M | 47.58M | 37M | 32.68M |
| Operating Expenses | 302.99M | 277.84M | 144.77M | 112.62M | 86.89M |
| Depreciation & Amortization | 4.73M | 5.5M | 3.5M | 3.13M | 2.99M |
| EBITDA | (296.56M) | (270.9M) | (130.39M) | (103.95M) | (81.96M) |
| EBITDA Margin | -16709.7% | -2639.8% | -15671.8% | -47735.2% | -125425.9% |
| Operating Income | (301.22M) | (267.57M) | (143.94M) | (112.4M) | (86.82M) |
| Operating Margin | -16972.3% | -2607.4% | -17300.3% | -51616.9% | -132871.3% |
| Interest Income | 3.36M | 4.78M | 8.13M | 4.77M | 2.42M |
| Interest Expense | 1.94M | 1.25M | 1.22M | 177.83K | 0 |
| Other Income / Expenses | (2.44M) | (12.24M) | 8.82M | 5.14M | 1.88M |
| Income Before Tax | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Pre-Tax Margin | -17109.9% | -2726.7% | -16239.9% | -49254.3% | -130000.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Net Margin | -17109.9% | -2726.7% | -16239.9% | -49254.3% | -130000.0% |
| EPS (Basic) | (1.42) | (14.07) | (6.09) | (3.95) | (1.81) |
| EPS (Diluted) | (1.42) | (14.07) | (6.09) | (3.95) | (1.81) |
| Weighted Avg Shares | 214.62M | 19.89M | 22.17M | 27.16M | 468.86M |
| Weighted Avg Shares (Diluted) | 214.62M | 19.89M | 22.17M | 27.16M | 468.86M |
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.